Protocol liver allograft biopsies

Transplantation

Volumn 85, Issue 12, 2008, Pages 1686-1692

  Mells, George ^a   Neuberger, James ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Liver transplantation; Protocol biopsies; Screening

Indexed keywords

CD30 ANTIGEN; GLUTATHIONE TRANSFERASE; HYALURONIC ACID; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; URSODEOXYCHOLIC ACID;

AUTOIMMUNE HEPATITIS; BLOOD EXAMINATION; CHRONIC GRAFT REJECTION; CHRONIC HEPATITIS; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMATOTHORAX; HEMOBILIA; HEMOPERITONEUM; HEPATITIS B; HEPATITIS C; HUMAN; HYDROTHORAX; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT; LIVER PAIN; MORBIDITY; MORTALITY; PERCUTANEOUS BIOPSY; PNEUMOTHORAX; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTOCOL LIVER ALLOGRAFT BIOPSY; RECURRENT DISEASE; REVIEW; SEPSIS; VEIN OCCLUSION; ALLOTRANSPLANTATION; BIOPSY; CLINICAL PROTOCOL; EDITORIAL; LIVER; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; PATHOLOGY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE;

BIOPSY; CLINICAL PROTOCOLS; HUMANS; LIVER; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 49149114788     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318176b1fd     Document Type: Review

References (73)

1. Neuberger J, Wilson P, Adams D. Protocol liver biopsies: The case in favour. Transplant Proc 1998; 30: 1497.
2. Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy. A multi-centre retrospective study on 67,276 biopsies. J Hepatol 1986; 2: 165.
3. Lindor KD, Bru C,Jorgensen RA,et al. The role ofultrasonography and automatic needle biopsy in outpatient percutaneous liver biopsy. Hepatology 1996; 23: 1079.
4. Farrell RJ, Smiddy PF, Pilkington RM, et al. Guided vs. blind liver biopsy for chronic hepatitis C: Clinical benefits and costs. J Hepatol 1999; 30: 580.
5. Bubak ME, Porayko MK, Krom RA, et al. Complicationsof liver biopsy in liver transplant patients: Increased sepsis associated with chole- dochojejunostomy. Hepatology 1991; 14: 1063.
6. Galati JS, Monsour HP, Donovan JP, et al. The nature of complications following liver biopsy in transplant patients with Roux-en-Y chole-dochojejunostomy. Hepatology 1994; 20: 651.
7. Ben-Ari Z, Neville L, Rolles K, et al. Liver biopsy in liver transplantation: No additional risk of infections in patients with choledochojejunostomy. J Hepatol 1996; 24: 324.
8. Chezmar JL, Keith LL, Nelson RC, et al. Liver transplant biopsies with a biopsy gun. Radiology 1991; 179: 447.
9. Van Thiel DH, Gavaler JS, Wright H, et al. Liver biopsy. Its safely and complications seen at a liver transplant center. Transplantation 1993; 55: 1087.
10. Pérez Roldán F, Bañares R, Clemente G, et al. Severe complications of percutaneous hepatic biopsy in patients with orthotopic liver transplantation. Gastroenterol Hepatol 1995; 18: 410.
11. Larson AM, Chan GC, Wartelle CF, et al. Infection complicating percutaneous liver biopsy in liver transplant recipients. Hepatology 1997; 26: 1406.
12. Lang M, Neumann UP, Muller AR, et al. Complications of percutaneous liver biopsy in patients after liver transplantation. Z Gastroenterol 1999; 37: 205.
13. Pasha T, Gabriel S, Therneau T, et al. Cost-effectiveness of ultrasound-guided liver biopsy. Hepatology 1998; 27: 1220.
14. Evans WK, Coyle D, Gafni A, et al. Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis. Chronic Dis Can 2003; 24: 102.
15. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523.
16. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898.
17. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614.
18. Poniachik J, Bernstein DE, Reddy KR, et al. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc 1996; 43: 568.
19. Grønbaek K, Christensen PB, Hamilton-Dutoit S, et al. Interobserver variation in interpretation of serial liver biopsies from patients with chronic hepatitis C. J Viral Hepat 2002; 9: 443.
20. Netto GJ, Watkins DL, Williams JW, et al. The hepatitis C 3 trial group. interobserver agreement in hepatitis C grading and staging and in the Banff grading schema for acute cellular rejection: the "hepatitis C 3" multi-institutional trial experience. Arch Pathol Lab Med 2006; 130: 1157.
21. Demetris AJ, Belle SH, Hart J, et al. Intraobserver and interobserver variation in the histopathological assessment of liver allograft rejection. The Liver Transplantation Database (LTD) Investigators. Hepatology 1991; 14: 751.
22. Lefkowitch JH. Liver biopsy assessment in chronic hepatitis. Arch Med Res 2007; 38: 634.
23. Colloredo G, Guido M, Sonzogni A, et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: The smaller the sample, the milder the disease. J Hepatol 2003; 39: 239.
24. Rousselet MC, Michalak S, Dupré F, et al. Hepatitis Network 49. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41: 257.
25. Saleh HA, Abu-Rashed AH. Liver biopsy remains the gold standard for evaluation of chronic hepatitis and fibrosis. J Gastrointestin Liver Dis 2007; 16: 425.
26. Slapak GI, Saxena R, Portmann B, et al. Graft and systemic disease in long-term survivors of liver transplantation. Hepatology 1997; 25: 195.
27. Pappo O, Ramos H, Starzl TE, et al. Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. Am J Surg Pathol 1995; 19: 192.
28. Berenguer M, Rayon JM, Prieto M, et al. Are prosttransplantation biopsies useful in the long term? Liver trasnpl 2001; 7: 790.
29. Sebagh M, Rifai K, Feray C, et al. All liver recipients benefit from the protocol 10-year liver biopsy. Hepatology 2003; 37: 1293.
30. Demetris AJ, Seaberg EC, Batts KP, et al. Chronic allograft rejection. Am J Surg Pathol 1998; 22: 28.
31. Weisner RH, Ludwig J, van Hoek B, et al. Current concepts in cellmediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology 1991; 14: 721.
32. Demetris A, Adams D, Bellamy C, et al. Update of the international Banff schema for liver allograft rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection. Hepatology 2000; 31: 792.
33. Weisner RH, Batts KP, Krom RAF. Evolving concepts in the diagnosis, pathogenesis, and treatmentofchronic hepatic allograft rejection.Liver Transpl Surg 1999; 5: 388.
34. Targhetta S, Villamil F, Inturri P, et al. Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease. World J Gastroenterol 2006; 12: 1706.
35. Everhart JE, Wei Y, Eng H, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999; 29: 1220.
36. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000; 32: 673.
37. Prieto M, Berenguer M, Rayón JM, et al. High incidence of allograft cirrhosisinhepatitis Cvirus genotype1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999; 29: 250.
38. FernándezI, Meneu JC, ColinaF,et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12: 1805.
39. Stravitz RT, Shiffman ML, Sanyal AJ, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004; 10: 850.
40. Dumortier J, Scoazec JY, Chevallier P, et al. Treatment of recurrent hepatitis C after liver transplantation: A pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669.
41. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: An open-label series. Transplantation 2004; 77: 190.
42. Babatin M, Schindel L, Burak KW. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy. Can J Gastroenterol 2005; 19: 359.
43. Gane E. Treatment of recurrent hepatitis C. Liver Transpl 2002; 8: S28.
44. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004; 10: 1240.
45. Reich DJ, Fiel I, Guarrera JV, et al. Liver transplantation for autoimmune hepatitis. Hepatology 2000; 32: 693.
46. Vogel A, Heinrich E, Bahr MJ, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004; 18: 62.
47. Ayata G, Gordon FD, Lewis WD, et al. Liver transplantation for autoimmune hepatitis: A long-term pathologic study. Hepatology 2000; 32: 185.
48. Kerkar N, Hadzic N, Davies ET, et al. Denovo autoimmune hepatitis after liver transplantation. Lancet 1998; 351: 409.
49. Banff Working Group. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006; 44: 489.
50. Heneghan MA, Portmann BC, Norris SM, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001; 34: 464.
51. Salcedo M, Vaquero J, Banares R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002; 35: 349.
52. Duclos-Vallee J-C, Sebagh M, Rifai K, et al. A 10 year followup study of patients transplanted for autoimmune hepatitis: Histological recurrence precedes clinical and biochemical recurrence. Gut 2003; 52: 893.
53. Neuberger J. Chronic allograft dysfunction: diagnosis and management. Is it always progressive? Liver Transpl 2005; 11: S63.
54. Hubscher SG. Chronic hepatitis in liver allografts. Hepatology 1990; 12: 1257.
55. Evans HM, Kelly DA, McKiernan PJ, et al. Progressive histological damage in liver allografts following paediatric liver transplantation. Hepatology 2006; 43: 1109.
56. Syn W-K, Nightingale P, Gunsen B, et al. Natural history of unexplained chronic hepatitis after liver transplantation. Liver Transpl 2007; 13: 984.
57. Dhillon AP, Burroughs AK, Hudson M, et al. Hepatic venular stenosis after orthotopic liver transplantation. Hepatology 1994; 19: 106.
58. Jacob DA, Neumann UP, Bahra M, et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transplant 2006; 20: 211.
59. Neuberger J. Recurrent primary biliary cirrhosis. Liver Transpl 2003; 9: 539.
60. Adam R, McMaster P, O'Grady JG, et al. Evolution of liver transplantation in Europe: Report of the European Liver Transplant Registry. Liver Transpl 2003; 9: 1231.
61. Mells G, Neuberger J. Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation 2007; 83: 1141.
62. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a non-renal organ. N Engl J Med 2003; 349: 931.
63. Galve ML, Cuervas-Mons V, Figueras J, et al. Incidence and outcome of de novo malignancies after liver transplantation. Transplant Proc 1999; 31: 1275.
64. Green M. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001; 1: 103.
65. Ramos HC, Reyes J, Abu-Elmagd K, et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 1995; 59: 212.
66. Devlin J, Doherty D, Thomson L, et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998; 27: 926.
67. Wong T, Nouri-Aria KT, Devlin J, et al. Tolerance and latent cellular rejection in long-term liver transplant recipients. Hepatology 1998; 28: 443.
68. Perkins JD, Nelson DL, Rakela J, et al. Soluble interleukin 2 receptor level in liver allograft recipients: an indicator of rejection. Transplant Proc 1989; 21: 2275.
69. Fábrega E, Castro B, Crespo J, et al. Different time course of circulating adhesion molecules and hyaluran during hepatic allograft rejection. Transplantation 2000; 69: 569.
70. Trull AK, Facey SP, Rees GW, et al. Serum alpha-glutathione S-transferase-a sensitive marker of hepatocellular damage associated with acute liver allograft rejection. Transplantation 1994; 58: 1345.
71. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): A prospective study. Gut 2006; 55: 403.
72. Toniutto P, Fabris C, Bitetto D, et al. Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation. J Gastro Hepatol 2007; 22: 1904.
73. Benlloch S, Berenguer M,Prieto M,et al. Prediction of fibrosisin HCV-infected liver transplant recipients with a simple non-invasive index. Liver Transpl 2005; 11: 456.